Epic Pharma, LLC received final FDA approval on September 22, 2015, for its ANDA for oxycodone hydrochloride oral solution, adding a critical generic alternative to the opioid market during a period of intense scrutiny. This approval enables Epic Pharma to supply a bioequivalent product, likely increasing generic competition for the branded oxycodone solution and pressuring pricing in the established opioid space.